Abstract 4361
Background
Despite an increasing incidence, vulvar squamous cell cancer (VSCC) is still a rare disease. So far two etiological pathways have been described: A high-risk human papillomavirus (HPV)-dependent route and an HPV–independent pathway often associated with lichen sclerosus. To date, therapeutic strategies in VSCC are not influenced by molecularpathological information and therapeutic options for advanced or recurrent disease are limited.
Methods
Whole exome sequencing of DNA isolated from 34 VSCC samples and matched normal tissue for each individual was performed on an Illumina HiSeq4000. Short variant discovery was carried out using BWA and MuTect2. Variants were annotated using ANNOVAR. For the detection structural variants and copy number aberrations, Pindel, ADTEx and FREEC were employed. Presence of HPV integration sites was assessed using Bowtie2.
Results
All pts (median age 60) received surgery with (partial) vulvectomy as primary treatment. In 82% a surgical staging of the groins was performed. FIGO stages were: n = 5 IB, n = 13 II, n = 5 stage III and n = 2 IVA (n = 7 unknown). 10/34 (29.4%) samples were HPV positive (all HPV16). 17.6% pts suffered from recurrence (4 local, 2 groin, 1 pelvic) after a median of 10 months. TP53 mutations were most commonly detected, with 41% (14/34). Additionally, we observed mutations in the following genes, which were affected in at least three samples: MUC3A (7/34), FSIP2 (4/34), AKAP9 (4/34), TDRD15, PKD1L1, FCHO1, RANBP2, FBXW7, VPS13C, MDGA2, SCN9A, VEPH1, ABCA5, KIAA0368, NCAM2, GCC2, MYCBP2, PRPF39, WDR49, ZNF729, UTRN, ANKRD36, GRAMD1c, ADGRV1 in 3/34 samples. Significantly less mutations were detected in pts with a OS > 48 months (p = 0.032). However, there was no significant difference in PFS or OS between HPV positive and negative tumors (p = 0.78 and 0.92). In an univariate analysis there was a significant correlation between HPV negative tumors and TP53 mutations (p < 0.0001). No correlation between pT status, pN status, tumor size or number of mutations and HPV status was detected.
Conclusions
The key mutation in vulvar cancer affects TP53. This first work and progress analysis of whole exome sequencing of VSCC with corresponding normal tissue has the potential to identify further key mutations and therewith new targets for the treatment of VSCC.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Hamburger Krebsgesellschaft.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract